Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents

187 Pages·2016·2.91 MB·English

by  Rudolph M. Navari (eds.)

Rudolph M. Navari Editor
Management of
Chemotherapy-
Induced Nausea
and Vomiting
New Agents and New Uses of
Current Agents
Management of Chemotherapy-Induced Nausea
and Vomiting

Rudolph M. Navari
Editor
Management of
Chemotherapy-Induced
Nausea and Vomiting
New Agents and New Uses of Current Agents
Editor
Rudolph M. Navari
Medicine
Indiana University School of Medicine
South Bend
Indiana
USA
ISBN 978-3-319-27014-2 ISBN 978-3-319-27016-6 (eBook)
DOI 10.1007/978-3-319-27016-6
Library of Congress Control Number: 2016930399
Springer Cham Heidelberg New York Dordrecht London
© Springer International Publishing Switzerland 2016
T his work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of
the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation,
broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information
storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology
now known or hereafter developed.
T he use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
T he publisher, the authors and the editors are safe to assume that the advice and information in this book
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the
editors give a warranty, express or implied, with respect to the material contained herein or for any errors
or omissions that may have been made.
Printed on acid-free paper
Adis is a brand of Springer
S pringer International Publishing AG Switzerland is part of Springer Science+Business Media
(www.springer.com)
Biogr aphy
Rudolph M. Navari , M.D ., Ph.D ., F.A.C.P .
Director , Cancer Care Program , Central and South America
World Health Organization
Professor of Medicine
Indiana University School of Medicine South Bend
Medical Director , Student Outreach Clinic
Indiana University School of Medicine South Bend
Dr. Navari received the Ph.D. degree at the University of Virginia and the M.D.
degree at the Medical College of Virginia. He received training in internal medicine
at the University of Alabama in Birmingham and was a fellow in hematology and
oncology at the Fred Hutchinson Cancer Research Center, University of Washington
School of Medicine. He is board certifi ed in internal medicine and medical oncol-
ogy. From 1983 to 1998, he served on the Clinical Faculty of the University of
Alabama Birmingham and was a practicing medical oncologist in the Simon-
Williamson Clinic. During this time, he was chairman of the Department of
Medicine and president of the Simon-Williamson Clinic, director of the Bone
Marrow Transplantation Program, and director of the Comprehensive Cancer
Program at Baptist Medical Center. In 1997, he was elected a fellow of the American
College of Physicians. During 1998–1999, he was a fellow in clinical medical ethics
in the MacLean Center for Clinical Medical Ethics at the University of Chicago. He
joined the faculty of the College of Science of the University of Notre Dame (UND)
in 1999 as director of the Walther Cancer Research Center. He was appointed asso-
ciate dean, College of Science, in 2000. In July, 2005, he became professor of medi-
cine, assistant dean, and director, Indiana University School of Medicine South
Bend (IUSM SB), and adjunct professor of biochemistry, University of Notre Dame.
In 2011, he was appointed clinical director, Harper Cancer Research Institute, a
partnership between IUSM SB and UND. He was promoted to associate dean in
2012. Along with the medical students at IUSM SB, he founded the IUSM SB
Student Outreach Clinic in 2013 and was appointed the Clinic’s fi rst medical
director.
v
vi Biography
I n 2014, he joined the World Health Organization as director of the Cancer Care
Program, Eastern Europe. In 2015, he was appointed director of the Cancer Care
Program, Central and South America.
Dr. Navari’s research interests include supportive care in clinical oncology,
development of antiemetics, palliative care, and the doctor-patient relationship in
clinical oncology. He has published over 130 peer-reviewed articles, with the most
recent dealing with supportive care issues in clinical oncology
Contents
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Rudolph M. Navari
2 The Physiology and Pharmacology of Nausea
and Vomiting Induced by Anticancer Chemotherapy in Humans . . . . . 5
Paul L. R. Andrews and John A. Rudd
3 First-Generation 5-HT3 Receptor Antagonists . . . . . . . . . . . . . . . . . . . 45
Roy Chen , Kathy Deng , and Harry Raftopoulos
4 Palonosetron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Lee Schwartzberg
5 The Role of Neurokinin-1 Receptor Antagonists in CINV . . . . . . . . . . 85
Bernardo Leon Rapoport
6 Olanzapine for the Prevention of Chemotherapy-Induced Nausea
and Vomiting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Rudolph M. Navari
7 Gabapentin for the Prevention of CINV . . . . . . . . . . . . . . . . . . . . . . . . 121
Thomas J. Guttuso Jr.
8 Prevention of CINV in Patients Receiving High-Dose Multiple-Day
Chemotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Luigi Celio
9 Clinical Management of CINV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
Rudolph M. Navari
vii
viii Contents
10 Treatment of Chemotherapy-Induced Nausea . . . . . . . . . . . . . . . . . . . 163
Rudolph M. Navari
11 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
Rudolph M. Navari
12 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
Rudolph M. Navari
Chapter 1
Introduction
Rudolph M. Navari
Chemotherapy-induced nausea and vomiting (CINV) is associated with a signifi cant
deterioration in quality of life and is perceived by patients as a major adverse effect
of the treatment [1 , 2 ]. Increased risk of CINV is associated with the type of chemo-
therapy administered (Table 1 .1 ) and specifi c patient characteristics (Table 1 .2 ) [3 ].
CINV can result in serious complications, such as weakness, weight loss, electrolyte
imbalance, dehydration, or anorexia, and is associated with a variety of complica-
tions, including fractures, esophageal tears, decline in behavioral and mental status,
and wound dehiscence [1 ] . Patients who are dehydrated, debilitated, or malnour-
ished, as well as those who have an electrolyte imbalance or those who have recently
undergone surgery or radiation therapy, are at greater risk of experiencing serious
complications from CINV [ 1 – 3 ].
The use of 5-hydroxytryptamine-3 (5-HT ) receptor antagonists plus dexametha-
3
sone has improved the control of CINV [4 ] . Recent studies have demonstrated some
improvement in the control of CINV with the use of a number of new agents: palo-
nosetron, a second-generation 5-HT receptor antagonist [4 ] ; neurokinin (NK)
3 1
receptor antagonists aprepitant [5 , 6 ] , netupitant [7 ] , and rolapitant [8 ] ; and olanzap-
ine, an antipsychotic that blocks multiple neurotransmitters in the central nervous
system [9 – 11 ].
The primary end point used for studies evaluating various agents for the control
of CINV has been complete response (no emesis, no use of rescue medication) over
the acute (24 h post-chemotherapy), delayed (24–120 h), and overall (0–120 h)
periods [3 ]. Recent studies have shown that the combination of a 5-HT receptor
3
antagonist, dexamethasone, and an NK receptor antagonist have improved the con-
1
trol of emesis in patients receiving either highly emetogenic chemotherapy (HEC)
R. M. Navari , MD, PhD, FACP
Cancer Care Program, Central and South America, World Health Organization , Indiana
University School of Medicine South Bend , South Bend , IN , USA
e-mail: [email protected]
© Springer International Publishing Switzerland 2016 1
R.M. Navari (ed.), Management of Chemotherapy-Induced Nausea
and Vomiting: New Agents and New Uses of Current Agents,
DOI 10.1007/978-3-319-27016-6_1